Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : NMK89 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ac-225, a core material used for TAT, a new therapeutic concept to attack cancer cells in body, applying a therapeutic agent in which alpha particle-emitting radionuclides that can kill cancer cells are bound to antibodies selectively accumulated in prot...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable
Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule
Details : 18-F FACBC is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 02, 2012
Reset All
